Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul>
<li>Advancing AI Nose beyond healthcare into smart manufacturing.</li>
<li>Ainos announced initial results from a VOC sensing program in industrial safety and smart manufacturing with its Japanese co-development partners.</li>
<li>As of August 15, 2024, AI Nose achieved 79% accuracy in detecting 22 different VOCs to identify 761 samples of potentially hazardous gases or contaminants. </li>
</ul>


Advancing AI Nose beyond healthcare into smart manufacturing.
Ainos announced initial results from a VOC sensing program in industrial safety and smart manufacturing with its Japanese co-development partners.
As of August 15, 2024, AI Nose achieved 79% accuracy in detecting 22 different VOCs to identify 761 samples of potentially hazardous gases or contaminants. 


Ainos, Inc.( AIMD): AI Nose Expanding into Industrial Smart Manufacturing

<ul><li>Ainos acquired exclusive, permanent licenses for 10 patents and patent applications from its affiliate and development partner, Taiwan Carbon Nano Technology (TCNT), for certain gas sensor and medical device technologies.</li><li>TCNT is also currently the sole manufacturer of Ainos’ POCTs. The patent coverage includes the US, Germany, China, Japan, and Taiwan.</li><li>The licensed IP will further enhance the company’s AI Nose and POCT platform, as the lead POCT product Ainos Flora progresses in clinical trial, and design completion for next-gen Ainos Flora with Nvidia CUDA is expected in 3Q24, with clinical <span style="font-size: var(--content-font-size);">trial starting in 4Q24. </span></li></ul>

Ainos acquired exclusive, permanent licenses for 10 patents and patent applications from its affiliate and development partner, Taiwan Carbon Nano Technology (TCNT), for certain gas sensor and medical device technologies.TCNT is also currently the sole manufacturer of Ainos’ POCTs. The patent coverage includes the US, Germany, China, Japan, and Taiwan.The licensed IP will further enhance the company’s AI Nose and POCT platform, as the lead POCT product Ainos Flora progresses in clinical trial, and design completion for next-gen Ainos Flora with Nvidia CUDA is expected in 3Q24, with clinical trial starting in 4Q24. 

Ainos, Inc. - AI Nose Patents Licensed from Key Partner with Shares Valued at a Premium

<ul><li>Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal clinical study for feline chronic gingivostomatitis (FCGS) and advancement of next-generation Ainos Flora with Nvidia CUDA implementation.</li><li>Financials. 2Q24 revenue was $0, as Ainos has pivoted away from COVID-19 antigen tests and focuses on AI Nose for the POCT platform and Veldona drugs.</li><li>Pet supplement product revenue in the quarter was deferred in contract liabilities. </li></ul>

Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal clinical study for feline chronic gingivostomatitis (FCGS) and advancement of next-generation Ainos Flora with Nvidia CUDA implementation.Financials. 2Q24 revenue was $0, as Ainos has pivoted away from COVID-19 antigen tests and focuses on AI Nose for the POCT platform and Veldona drugs.Pet supplement product revenue in the quarter was deferred in contract liabilities. 

<ul><li>Ainos business and priorities. The medtech company has three key technology platforms: (1) AI Nose point of care testing (POCT); (2) Low dose interferon-α Veldona; and (3) Synthetic RNA in early discovery stage.</li><li>Priorities for AI Nose are Ainos Flora (POCT diagnostic for women vaginal health and STIs) and a health monitor system for elderly care in co-development.</li><li>Veldona will focus on oral warts in HIV+ patients and Sjogren’s syndrome, in addition to cat FCGS (gum disease) for animal health.</li></ul>

Ainos business and priorities. The medtech company has three key technology platforms: (1) AI Nose point of care testing (POCT); (2) Low dose interferon-α Veldona; and (3) Synthetic RNA in early discovery stage.Priorities for AI Nose are Ainos Flora (POCT diagnostic for women vaginal health and STIs) and a health monitor system for elderly care in co-development.Veldona will focus on oral warts in HIV+ patients and Sjogren’s syndrome, in addition to cat FCGS (gum disease) for animal health.

Ainos, Inc. Water Tower Hour Recap: AI Nose for POCT Diagnostics and Much More

<ul><li>Enrolled first subject in feline oral disease study, paving way for animal health opportunity.</li><li>The randomized, double- blind Veldona animal study will enroll 30 cats with feline chronic gingivostomatitis (FCGS) at a single Taiwan clinical site.</li><li>Two dosage groups, a low dose (6,000 IU) and high dose (12,000 IU), will be evaluated. The first enrolled subject will be dosed later this week. </li></ul>

Enrolled first subject in feline oral disease study, paving way for animal health opportunity.The randomized, double- blind Veldona animal study will enroll 30 cats with feline chronic gingivostomatitis (FCGS) at a single Taiwan clinical site.Two dosage groups, a low dose (6,000 IU) and high dose (12,000 IU), will be evaluated. The first enrolled subject will be dosed later this week. 

Ainos, Inc. - Veldona Animal Study Enrolls First Subject, Marking a Good Start

United States

Ainos, Inc. is a diversified healthcare company. The Company engages in the discovery and development of novel biopharmaceuticals, technologically medical treatments, and consumer products, as well as provides treatments of neoplastic, viral, and autoimmune diseases. Ainos operates in the United States and Taiwan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ainos (AIMD US)

Ainos, Inc.( AIMD): AI Nose Expanding into Industrial Smart Manufacturing

The results support AI Nose’s potential application in industrial automation and improving manufacturing safety monitoring.

Water Tower Research

Ainos, Inc. - AI Nose Patents Licensed from Key Partner with Shares Valued at a Premium

Ainos is also exploring to deploy VOC sensing to enable a safer work environment and better production quality in high-tech factories.

Water Tower Research

Ainos, Inc. - Earnings Update

Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal...

Water Tower Research

Ainos, Inc. Water Tower Hour Recap: AI Nose for POCT Diagnostics and Much More

The medtech company has three key technology platforms: (1) AI Nose point of care testing (POCT); (2) Low dose interferon-α Veldona; and (3)...

Water Tower Research

Ainos, Inc. - Veldona Animal Study Enrolls First Subject, Marking a Good Start

Positive results would support a pivotal field study for animal drug approval in Taiwan, marking a good start in Veldona animal drug development...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)